| Literature DB >> 35200667 |
Beomkoo Chung1, Ji-Yeon Hwang2, Sung Chul Park2, Oh-Seok Kwon2, Eunji Cho1, Jayho Lee1, Hyi-Seung Lee3, Dong-Chan Oh2, Jongheon Shin2, Ki-Bong Oh1.
Abstract
Two nitrogenous metabolites, bacillimide (1) and bacillapyrrole (2), were isolated from the culture broth of the marine-derived actinomycete Streptomyces bacillaris. Based on the results of combined spectroscopic and chemical analyses, the structure of bacillimide (1) was determined to be a new cyclopenta[c]pyrrole-1,3-dione bearing a methylsulfide group, while the previously reported bacillapyrrole (2) was fully characterized for the first time as a pyrrole-carboxamide bearing an alkyl sulfoxide side chain. Bacillimide (1) and bacillapyrrole (2) exerted moderate (IC50 = 44.24 μM) and weak (IC50 = 190.45 μM) inhibitory effects on Candida albicans isocitrate lyase, respectively. Based on the growth phenotype using icl-deletion mutants and icl expression analyses, we determined that bacillimide (1) inhibits the transcriptional level of icl in C. albicans under C2-carbon-utilizing conditions.Entities:
Keywords: Candida albicans; Streptomyces bacillaris; bacillapyrrole; bacillimide; isocitrate lyase
Mesh:
Substances:
Year: 2022 PMID: 35200667 PMCID: PMC8878140 DOI: 10.3390/md20020138
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The structures of bacillimide (1), benzoyl bacillimide (1a) and bacillapyrrole (2).
1H and 13C NMR data of compounds 1 and 2 in DMSO-d6 (δH and δC in ppm).
| No. | 1 a | 2 b | ||
|---|---|---|---|---|
| 2 | 179.4, C | 121.4, CH | 6.83, d (1.5) | |
| 3 | 57.0, C | 108.6, CH | 6.07, t (2.0) | |
| 4 | 33.7, CH2 | 2.18, ddd (13.0, 6.5, 1.5) | 110.0, CH | 6.74, d (1.5) |
| 2.07, dd (13.0, 6.0) | ||||
| 5 | 33.6, CH2 | 1.76, ddd (13.5, 6.5, 1.5) | 126.0, C | |
| 1.50, ddd (13.0, 7.0, 2.5) | ||||
| 6 | 74.2, CH | 4.26, br s | 160.8, C | |
| 7 | 62.4, CH | 2.85, s | ||
| 8 | 176.4, C | 32.6, CH2 | 3.60, ddd (14.0, 6.0, 1.5) | |
| 3.52, ddd (14.0, 7.0, 1.5) | ||||
| 9 | 12.5, CH3 | 2.14, s | 53.6, CH2 | 3.00, ddd (13.0, 6.5, 1.0) |
| 2.86, ddd (13.0, 6.0, 1.0) | ||||
| 10 | 38.1, CH3 | 2.58, s | ||
| 1-NH | 11.49, br s | 11.45, br s | ||
| 6-OH | 5.28, s | |||
| 7-NH | 8.26, t (4.5) | |||
a 1H and 13C NMR data were recorded at 800 and 200 MHz, respectively. b 1H and 13C NMR data were recorded at 600 and 150 MHz, respectively.
Figure 2Key correlations of COSY (bold) and HMBC (arrows) experiments for compounds 1 and 2.
Figure 3Key correlations of NOESY (arrow) experiments for compounds 1 and 1a.
Figure 4Experimental CD and ECD calculations of bacillimide (1) and benzoyl bacillimide (1a).
Inhibitory activity of isolated compounds against the ICL enzyme and growth of C. albicans ATCC10231.
| Compound | ICL IC50 (μM) | MIC (μM) in Glucose |
|---|---|---|
| Bacillimide ( | 44.24 ± 1.05 | >1273.64 |
| Bacillapyrrole ( | 190.45 ± 3.86 | >1280.00 |
| 3-Nitropropionate | 21.49 ± 0.97 | >2149.46 |
| Amphotericin B | ND | 0.5 |
3-Nitropropionate and amphotericin B were used as a standard inhibitor of ICL and a representative antifungal drug, respectively. ND: not determined.
Figure 5Inhibitor type of bacillimide (1). Lineweaver–Burk plot of ICL inhibition by bacillimide (1). [S] and V represent the substrate concentration (mM) and reaction velocity (ΔAbsorbace324nm/sec), respectively. Each data point shows the mean of three independent experiments.
Inhibitory effect of bacillimide (1) on five C. albicans strains grown in glucose and acetate as sole carbon sources.
| Strain | MIC (μg/mL) | |||
|---|---|---|---|---|
| Glucose | Acetate | |||
| Bacillimide (1) | Amph B 1 | Bacillimide (1) | Amph B 1 | |
| SC5314 | >1024 | 0.5 | 256 | 0.5 |
| ATCC10231 | >1024 | 0.5 | 256 | 0.5 |
| ATCC10259 | >1024 | 0.5 | 256 | 0.5 |
| ATCC11006 | >1024 | 1 | 256 | 0.5 |
| ATCC18804 | >1024 | 1 | 256 | 1 |
C. albicans (2.5 × 103 cfu/mL) were incubated with various concentrations of bacillimide (1) for 2 days at 28 °C in YNB broth containing 2% glucose and 2% potassium acetate. 1 Amphotericin B (Amph B) was used as a standard antifungal drug.
Figure 6Analysis of growth phenotypes and icl expression in presence of bacillimide (1). (a) C. albicans SC5314 (wild-type strain), MRC10 (Δicl) (icl-deletion strain) and MRC11 (Δicl + ICL) (icl-complementary strain) were cultured on YNB agar plates with 2% glucose or 2% potassium acetate containing 0 µg/mL or 256 µg/mL bacillimide (1) for 2 days at 28 °C. (b) Mid-log phase of three C. albicans strains in YNB broth containing 2% glucose (Glu) were untreated, while those in YNB broth containing 2% potassium acetate (Ace) were treated with various concentrations of bacillimide (1) (C1: 64 µg/mL, C2: 128 µg/mL, C3: 256 µg/mL) and incubated for 4 h at 28 °C. Total RNA was extracted, and icl expression was analyzed with semiquantitative RT–PCR. GAPDH, a housekeeping gene, was used as a positive control.